Search





Search





Markets
/
Stocks
/
nasdaq-pmcb
/

PharmaCyte Biotech Inc

PMCB

Add to Watchlist

0.804USD

-0.146-15.38%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

8.64MMarket Cap

LossP/E TTM



PharmaCyte Biotech Inc

0.804

-0.146-15.38%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PharmaCyte Biotech Inc

Currency: USD Updated: 2026-05-15

Key Insights

PharmaCyte Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 202 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PharmaCyte Biotech Inc's Score

Industry at a Glance

Industry Ranking

202 / 382

Overall Ranking

404 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

PharmaCyte Biotech Inc Highlights

StrengthsRisks

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -0.90, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.07M shares, increasing 24.50% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 94.04K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of PharmaCyte Biotech Inc is 6.98, ranking 146 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.50

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

PharmaCyte Biotech Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of PharmaCyte Biotech Inc is 7.13, ranking 158 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.90, which is -2523.75% below the recent high of 21.89 and -1489.83% above the recent low of -14.36.

Score

Industry at a Glance

Previous score

7.13

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 202/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

No earnings forecast score is currently available for PharmaCyte Biotech Inc. The Biotechnology & Medical Research industry's average is 8.13.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of PharmaCyte Biotech Inc is 6.97, ranking 118 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.96 and the support level at 0.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.00

Change

-2.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.020

Buy

RSI(14)

53.274

Neutral

STOCH(KDJ)(9,3,3)

62.963

Neutral

ATR(14)

0.082

High Vlolatility

CCI(14)

127.836

Buy

Williams %R

55.182

Sell

TRIX(12,20)

0.449

Sell

StochRSI(14)

37.788

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.810

Sell

MA10

0.787

Buy

MA20

0.770

Buy

MA50

0.731

Buy

MA100

0.757

Buy

MA200

0.848

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of PharmaCyte Biotech Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 9.99%, representing a quarter-over-quarter increase of 132.81%. The largest institutional shareholder is James Simons, holding a total of 56.50K shares, representing 0.53% of shares outstanding, with 27.02% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Silverman (Joshua)

366.25K

-21.45%

Citadel Advisors LLC

229.72K

+1480.91%

HRT Financial LP

182.80K

Schechter (Jonathan L)

132.50K

-31.17%

Geode Capital Management, L.L.C.

123.84K

-2.18%

Sabby Management, LLC

100.00K

Renaissance Technologies LLC

Star Investors

94.04K

+17.54%

Weinstein (Robert)

41.25K

Northern Trust Investments, Inc.

35.60K

+85.34%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PharmaCyte Biotech Inc is 1.34, ranking 310 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.